8-K: Azenta Reports Mixed Q1 FY26 Results, Reaffirms Outlook

Azenta, Inc. announced its first quarter fiscal 2026 financial results, reporting revenue consistent with expectations but facing gross margin challenges, while reaffirming its full-year guidance.

Summary

• Revenue from continuing operations for the first quarter ended December 31, 2025, was $149 million, a 1% increase year-over-year.
• Organic revenue from continuing operations declined 1% year-over-year.
• Sample Management Solutions revenue was $81 million (flat year-over-year, organic decline of 2%).
• Multiomics revenue was $67 million (up 1% year-over-year, organic flat).
• GAAP diluted EPS from continuing operations improved to ($0.11) from ($0.16) in the prior year.
• Total diluted EPS was ($0.34), compared to ($0.25) a year ago, primarily due to losses from discontinued operations.
• Non-GAAP diluted EPS from continuing operations was $0.09, down from $0.12 in the prior year.
• Adjusted EBITDA from continuing operations was $13 million, with an Adjusted EBITDA margin of 8.5%, a decrease of 230 basis points year-over-year.
• Gross margin was 42.9%, down 380 basis points year-over-year, mainly due to lost cost leverage from lower sales volumes and rework costs on Automated Stores projects.
• Operating expenses decreased 8% year-over-year to $71 million.
• The company ended the quarter with $571 million in cash, cash equivalents, restricted cash, and marketable securities.
• Operating cash flow was $21 million, and free cash flow was $15 million.
• Azenta reiterated its full-year fiscal 2026 guidance, expecting total organic revenue growth of 3% to 5% and Adjusted EBITDA margin expansion of approximately 300 basis points.
• The sale of B Medical Systems for $63 million is expected to close on or before March 31, 2026, with its results treated as discontinued operations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While revenue met expectations and free cash flow was strong, significant declines in gross margin, Non-GAAP EPS, and Adjusted EBITDA, coupled with a larger loss from discontinued operations, temper the positive aspects. The reaffirmed guidance for the full year and expectation for a stronger second half provide some optimism, but the 'turnaround' narrative suggests ongoing challenges.

Positives

• Revenue performance was consistent with management's expectations, showing a 1% year-over-year increase for continuing operations.
• Generated strong free cash flow of $15 million in the quarter, reflecting operational discipline and working capital management.
• GAAP diluted EPS from continuing operations improved to ($0.11) from ($0.16) year-over-year.
• Operating loss improved to ($7.2 million) from ($8.7 million) year-over-year, with operating margin up 100 basis points.
• Operating expenses decreased by 8% year-over-year, driven by lower selling, general and administrative expenses.
• The company maintains a strong liquidity position with $571 million in cash, cash equivalents, restricted cash, and marketable securities.
• Reiterated full-year fiscal 2026 guidance for organic revenue growth (3% to 5%) and Adjusted EBITDA margin expansion (approximately 300 basis points), indicating confidence in future performance, particularly a stronger second half.

Negatives

• Organic revenue from continuing operations declined 1% year-over-year.
• Gross margin decreased by 380 basis points year-over-year to 42.9%, primarily due to lost cost leverage from lower sales volumes and rework costs on Automated Stores projects.
• Non-GAAP diluted EPS from continuing operations declined to $0.09 from $0.12 in the prior year.
• Adjusted EBITDA from continuing operations decreased to $13 million from $16 million year-over-year, with the margin declining by 230 basis points to 8.5%.
• Total diluted EPS worsened to ($0.34) from ($0.25) a year ago, largely due to a significant loss from discontinued operations ($10.242 million vs. $3.919 million).
• Organic revenue in Sample Management Solutions declined 2%, mainly driven by lower revenues in Core Products (Automated Stores and Cryogenic Systems).

Risks

• Uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US.
• Ability to effectively reduce costs.
• Volatility of the life sciences markets served by the company.
• Possible inability to meet demand for products due to difficulties in obtaining components and materials from suppliers in required quantities and quality.
• Inability of customers to make payments when due.
• Competition within the life sciences solutions market.

Future Outlook

Azenta is reiterating its full-year fiscal 2026 guidance, expecting total organic revenue growth in the range of 3% to 5% relative to fiscal 2025, and Adjusted EBITDA margin expansion of approximately 300 basis points. Management anticipates a stronger second half of the year, supported by ongoing execution initiatives, and remains confident in its long-range plan through 2028 for sustainable growth and long-term value creation.

Management Comments

• "We delivered revenue performance consistent with our expectations. We also generated strong free cash flow in the quarter, reflecting our continued focus on operational discipline and working capital management."
• "We saw challenges on the gross margin line, and our turnaround continues, and in any turnaround, it is never a straight line."
• "We remain committed to our fiscal 2026 objectives and our expectation for a stronger second half of the year, supported by our ongoing execution initiatives."
• "We are equally confident in our long-range plan outlined at Investor Day, which extends through 2028 and supports sustainable growth and long-term value creation."

Industry Context

StockSavvy.ai notes that the life sciences tools and services sector, while generally robust, can experience volatility influenced by research funding cycles, biotech investment trends, and global economic conditions. Azenta's mixed results, with flat organic revenue and gross margin pressures, suggest that even leading players are navigating a complex environment. The company's focus on operational discipline and a 'turnaround' narrative indicates a strategic effort to optimize performance amidst these dynamics, aligning with broader industry trends of efficiency and targeted growth in high-potential areas like Next Generation Sequencing.

Comparison to Industry Standards

• Azenta's 1% year-over-year revenue growth and -1% organic growth for continuing operations are below the average growth rates seen in some high-growth segments of the life sciences tools industry, where companies like Illumina (sequencing) or Danaher (diversified life sciences) often target mid-to-high single-digit organic growth. However, it's important to consider Azenta's specific portfolio, which includes both mature and growth-oriented segments.
• The decline in gross margin by 380 basis points to 42.9% is a notable concern. Leading life science tool providers typically maintain gross margins in the 50-70% range, reflecting strong intellectual property and pricing power. Azenta's current gross margin, particularly with the decline, suggests challenges in cost management or pricing power compared to industry leaders.
• The Adjusted EBITDA margin of 8.5% is also on the lower end compared to many established life science companies, which often achieve EBITDA margins in the 20-35% range. This indicates significant room for operational efficiency improvements as part of the company's stated turnaround.
• The strong free cash flow generation of $15 million is a positive, demonstrating effective working capital management, which is a key operational strength even when profitability metrics are under pressure. This is a good sign for financial stability, comparable to well-managed companies across various industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Mixed financial results with declining profitability metrics may cause concern, but the reaffirmed full-year guidance and new share repurchase program could provide confidence in future value creation. The sale of B Medical Systems simplifies the business structure.
• Employees: The mention of 'restructuring charges' and 'transformation costs' suggests ongoing organizational changes, which could impact employees through potential job reassignments or reductions, though specific details are not provided.
• Customers: Challenges in Sample Management Solutions, particularly in Automated Stores and Cryogenic Systems, could indicate potential service or product delivery issues, though overall revenue was stable. Growth in Next Generation Sequencing and Gene Synthesis suggests continued innovation in Multiomics.
• Suppliers: Difficulties in obtaining components and materials, as mentioned in risks, could impact supplier relationships and demand for their products/services.
• Creditors: Strong cash and liquidity position, along with positive free cash flow, indicates a healthy financial standing to meet obligations.

Next Steps

• Closing of the sale of B Medical Systems business, expected on or before March 31, 2026.
• Continued execution of initiatives to achieve fiscal 2026 objectives, including 3% to 5% organic revenue growth and approximately 300 basis points of Adjusted EBITDA margin expansion.
• Focus on achieving a stronger second half of fiscal year 2026.
• Potential share repurchases under the new $250 million program through December 31, 2028.
• Ongoing execution of the long-range plan through 2028 to support sustainable growth and long-term value creation.

Key Dates

Recommendation

The filing presents a mixed picture. While revenue met expectations and free cash flow was strong, key profitability metrics like gross margin, Non-GAAP EPS, and Adjusted EBITDA declined significantly. The reaffirmed full-year guidance and the new share repurchase program signal management's confidence in a stronger second half and long-term value. However, the acknowledged 'turnaround' and ongoing gross margin challenges suggest that significant improvements are still needed. A 'hold' recommendation allows investors to observe the execution of the turnaround strategy and the realization of the anticipated stronger second half before making further investment decisions.

Keywords

Azenta, AZTA, Financial Results, Earnings, Life Sciences, Sample Management, Multiomics, SEC Filing, Q1 2026, Biotech, Pharmaceutical, Cold Chain, Corporate Governance